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Abstract
Up to date causal relationship has been demonstrated between dental manipulations
and the onset of infective endocarditis (IE). However, since 1955, numerous expert
committees have proposed antibiotic prophylaxis (AP) to prevent bacteraemia of oral
origin. Controversy regarding the efficacy of AP prior to the dental procedures has
intensified in recent years because of the lack of conclusive evidence on its efficacy for
the prevention of IE and on its cost-effectiveness, as well as the possibility of allergic
reactions and the emergence of antibiotic resistance. Accordingly, AP is now maintained
exclusively for patients at highest risk and who require the manipulation of the gingival
or periapical regions of the teeth or perforation of the oral mucosa. In the context of a
restrictive policy, the National Institute for Health and Clinical Excellence (NICE) of the
United Kingdom published a new guideline in 2008 stating that “AP against IE is not
recommended for persons undergoing dental procedures”, regardless of risk status and
of the nature of the procedure to be performed. The NICE guideline has generated
further  controversy,  and expert  committees  in  other  countries  continue to  publish
prophylactic regimens for the prevention of IE secondary to dental procedures. In this
chapter, we discuss the principal guidelines currently applicable in Europe, the USA
and Australia, and we draw particular attention to the need for randomised clinical
trials.
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1. Historical perspectives
In 1955, the American Heart Association (AHA) was the first medical society to establish the
need for a prophylactic antibiotic regimen to prevent infective endocarditis (IE) in at-risk
patients undergoing various surgical procedures, including tooth extractions and other dental
manipulations that affect the gum.
In the pre-antibiotic era, reports based on clinical observations described cases of IE of
streptococcal aetiology in which there was a history of professional dental manipulation. This
suggested the possibility that “transient bacteraemia during dental procedures may lead to
subacute endocarditis in subjects with abnormal heart valves” [1].
The 1955 AHA Committee on the Prevention of Rheumatic Fever and Bacterial Endocarditis
concluded that patients undergoing dental procedures must be protected by high concentra-
tions of antibiotic present in the blood at the time of the procedure. Penicillin administered
parenterally was preferred, although oral penicillin V was introduced as second choice. In
cases of sensitivity to penicillin, other antibiotics such erythromycin or tetracycline were
recommended [2].
Since that time, the scientific community has universally accepted the need for antibiotic
prophylaxis in patients susceptible to developing IE. Experimental models developed in the
1970s provided evidence of the efficacy of prophylaxis in animals and demonstrated the ability
of antibiotics to prevent Streptococcus sanguinis endocarditis [3]. However, the different
antibiotic regimens to prevent IE in dental patients were developed based on empirical criteria.
In 1982, the British Society for Antimicrobial Chemotherapy included amoxicillin in the
prophylactic antibiotic regimen against IE [4]. Amoxicillin has a broad antibacterial spectrum
and a more favourable pharmacokinetic profile than penicillin V for oral administration; this
has made it the drug of choice in all current guidelines on the use of antibiotics to prevent IE.
The main inclusion criteria for the prophylactic regimens established by the first committees
were the rheumatic heart disease and congenital malformations, but fundamental changes
have been introduced since that time regarding “patients considered to be at risk of IE”. The
campaigns for the prevention of rheumatic fever, the increase in the prevalence of intravenous
drug abuse and the growth in cardiovascular interventions have transformed the microbio-
logical patterns of IE, with a relative decrease in the incidence of streptococcal endocarditis
and a significant increase in endocarditis due to staphylococci and other less common
organisms.
These changes make it difficult to draw reliable epidemiological conclusions on the efficacy of
antibiotics for the prevention of IE. In general, the majority of studies indicate that, despite the
universal implantation of antibiotic prophylaxis prior to the dental treatment, no global
reduction in the prevalence of IE has been achieved [5].
This has been one of the main arguments put forward by the British health authorities to revoke
the indications for antibiotic prophylaxis in patients undergoing dental, digestive tract or
genitourinary interventions. A few years ago, the National Institute for Health and Clinical
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Excellence (NICE) in the United Kingdom published a proposal that surprised the scientific
community by considering that “antibiotic prophylaxis for IE was not recommended for
persons undergoing dental treatment”. This recommendation was even applicable to “high-
risk patients, independently of the type of dental procedure they were to undergo” [6].
This scepticism of the British health authorities to the prophylactic efficacy of antibiotics in IE
is not shared by other scientific societies, which continue to include antibiotic cover for dental
procedures in patients at risk of developing IE.
Epidemiological observations and statistical analyses made after the cessation of prophylaxis
in the United Kingdom suggest the need for antibiotic cover in patients at maximum risk of IE
of poor prognosis. In this setting, current guidelines maintain the need for prevention for
patients considered to be at high risk of developing IE, such as individuals with prosthetic
heart valves, the presence of certain congenital cardiopathies and patients who have had a
previous episode of IE.
2. Impact of the nice recommendations
In the controversial document published in 2008, NICE brought about the complete cessation
of antibiotic prophylaxis for all patients at risk of IE undergoing dental interventions [6]. The
main premises on which the British experts based this decision was the quantifiable risk of
antibiotic administration to the individual patient, the potential appearance of unnecessary
antimicrobial resistance and the economic analysis of the cost-effectiveness of prophylaxis.
The recommendation was based on the limited available evidence on antibiotic prophylaxis
as an effective method to reduce the incidence of IE when given before an interventional
procedure. Furthermore, the existence of transient bacteraemia during activities of daily living,
such as toothbrushing or chewing, diminishes the significance of dental procedures as a cause
of IE, making antibiotic prophylaxis virtually ineffective for preventing the disease.
Consequently, NICE did not recommend antibiotic prophylaxis against IE in persons under-
going dental procedures or digestive, respiratory or genitourinary tract interventions, except
for manipulations at an infected non-dental site.
The expert committees across the rest of the world, including the AHA and the European
Society of Cardiology (ESC), have continued to recommend antibiotic prophylaxis in high-risk
individuals, and these protocols are followed by most cardiologists and cardiac surgeons.
The first studies on the epidemiological repercussions of the implementation of the NICE
guideline showed a substantial reduction in the prescription of antibiotics in its area of
influence and the data gathered showed no significant changes in the general upward trend
in cases of IE [7].
In 2013, a case of IE was reported in which aetiological analysis suggested a very strong
association with a previous dental intervention performed without antibiotic cover. The
affected patient had a metallic aortic valve and developed a fatal episode of S. sanguinis
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endocarditis 10 days after undergoing a dental procedure without antibiotic prophylaxis,
following the NICE recommendations. The dental history of the patient showed that he had
received antibiotic prophylaxis during dental sessions over the previous 10 years with no
adverse outcomes [8].
The most recent epidemiological studies have identified a significant increase in the incidence
of IE after implementation of the NICE guideline. A retrospective study was performed in
England to investigate the effect of antibiotic prophylaxis versus no prophylaxis on the
incidence of IE [9]. The data collected and the subsequent analysis suggested that after March
2008—the year of publication of the NICE guideline—the number of cases of IE increased
significantly above the expected historical trend.
According to some experts, these data are mainly observational and do not prove that the lower
level of antibiotic prophylaxis was the cause of the increase in IE. However, no other satisfac-
tory explanation for this increase in the incidence of IE has yet been put forward [10].
Despite this, NICE has reviewed all evidence relating to the effectiveness of IE prophylaxis as
a precaution but, at present, they have found no need to change any of the existing 2008
guideline. They have, however, made an additional research recommendations on antibiotic
prophylaxis against IE as summarised in Table 1.
Field of research Importance
1. National register of infective
endocarditis
To provide a cohort of patients able to generate sufficient evidence from well-
conducted national studies
2. Cardiac conditions and
infective endocarditis
To use a population-based cohort study design to allow direct comparison between
acquired heart valve disease and structural congenital heart disease to estimate
relative and absolute IE risk
3. Interventional procedures and
infective endocarditis
To determine the frequency and intensity of bacteraemia caused by non-oral daily
activities
4. Antibiotic prophylaxis against
infective endocarditis
A randomised controlled trial with long-term follow-up comparing antibiotic
prophylaxis with no antibiotic prophylaxis in adults and children with underlying
structural heart defects undergoing interventional procedures
Note: https://nice.org.uk/guidance/CG64/chapter/Recommendations-for-research#4-antibiotic-prophylaxis-against-
infective-endocarditis
Table 1. NICE recommendations for research. Antimicrobial prophylaxis against infective endocarditis in adults and
children undergoing interventional procedures (updated in 2015).
3. Current antibiotic protocols
Antibiotic prophylaxis protocols against IE have undergone relevant changes in recent years.
There is no doubt that the categorical 2008 NICE recommendations and their implementation
in their area of influence constitute an event with significant epidemiological repercussions
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that will serve to evaluate the efficacy of antibiotic prophylaxis for the prevention of IE. The
scientific societies responsible for this question continue detailed follow-up in order to
incorporate their conclusions as relevant data arise.
Among the different prophylaxis guidelines proposed by expert committees around the world,
those that represent their corresponding geographical areas stand out for their scientific
relevance. In the USA, the AHA has been pioneer in the introduction of antibiotic prophylaxis
against IE; its most recent guideline was published in 2007 [11]. In Australia, the Infective
Endocarditis Prophylaxis Expert Group (AIEPEG) published a guideline in 2008 that has been
supported by the principal health associations in its area of influence [12]. In Europe, the ESC
published the 2015 review of its protocols in the European Heart Journal, stating the official
position of that scientific society on this subject [13]. These three guidelines coincide on two
major points:
• All propose amoxicillin as the antibiotic of choice.
• All propose clindamycin as the alternative antibiotic of choice to amoxicillin.
3.1. Amoxicillin as the antibiotic of choice for prophylaxis
The standard regimens of the three guidelines mentioned above recommend the oral admin-
istration of 2 g of amoxicillin between 30 and 60 min before a dental procedure in adults. In
the case of children, the recommended dose is 50 mg/kg body weight. When oral administra-
tion is not possible, amoxicillin can be administered intramuscularly or intravenously at the
same dose.
Amoxicillin was introduced into the IE prophylaxis protocols in 1982 [4] and since that time it
has become the drug of choice in the prophylactic guidelines internationally. From a pharma-
cological point of view, amoxicillin has optimal characteristics due to its rapid absorption after
administration by mouth, achieving maximum plasma concentrations within 1–2 h after
ingestion, and therapeutic levels are maintained for a minimum of 6 h. Amoxicillin is highly
active against streptococci and also covers anaerobes and gram-negative bacteria. It is thus
effective against the majority of microorganisms present in bacteraemia of oral origin.
However, it is considered that between 5 and 35% of the microorganisms detected in blood
cultures from patients undergoing dental treatment can be resistant to the antibiotic. This
finding, together with the increased prevalence of IE caused by penicillin-resistant staphylo-
cocci and other unusual microorganisms, could justify the introduction of antibiotics other
than amoxicillin into standard prophylaxis protocols in the future in order to improve the
antimicrobial spectrum in certain circumstances.
3.2. Alternative drugs to amoxicillin
The three guidelines incorporate cephalosporins for parenteral administration as an alterna-
tive to amoxicillin. The cephalosporins are also recommended in patients with penicillin
allergy, though this proposal is accompanied by a warning that the use of cephalosporins is
contraindicated in individuals with a history of anaphylaxis.
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About 10% of patients attending dental consultations are allergic to penicillin and its deriva-
tives, although a large majority of these reported allergic reactions are no more than minor
side-effects or late hypersensitivity reactions presenting as pruritus or rash, but not IgE-
mediated. Urticaria (hives) is IgE-mediated; it only accounts for 10% of all exanthematous drug
reactions, but may be interpreted as a clinical sign of immediate hypersensitivity that could
progress to an episode of acute (fulminant) anaphylaxis.
The main antigenic determinant of the anaphylactic reaction to penicillins is the β-lactam ring,
a part of the molecule that is essential for its bactericidal activity and that also forms part of
the chemical structure of the cephalosporins and clavulanates (clavulanic acid), among others.
Drug-related anaphylaxis is a life-threatening medical emergency and, as a result, the admin-
istration of β-lactam drugs is contraindicated in patients who give a history of penicillin allergy
until such time as allergy testing establishes the true risk of anaphylaxis in each individual
case [14].
The three main guidelines coincide on the oral or intravenous administration of 600 mg of
clindamycin as the antibiotic of choice in patients allergic to penicillins (Table 2). Clindamycin
has intrinsic in vitro activity against streptococci, staphylococci and anaerobes, it rarely causes
allergic reactions and it has a low incidence of side-effects, making it an ideal alternative
antibiotic based on its antimicrobial spectrum and biosafety. However, some authors have
demonstrated that it is ineffective in preventing bacteraemia following dental procedures [15].
Australia (AIEPEG) Europe (ESC) USA (AHA)
Clindamycin
Lincomycin
Vancomycin
Teicoplanin
Clindamycin Clindamycin
Azithromycin
Clarithromycin
Abbreviations: AIEPEG, Australian Infective Endocarditis Prophylaxis Expert Group; ESC, European Society of
Cardiology; AHA, American Heart Association.
Table 2. Alternative antibiotics for prophylaxis against infective endocarditis in patients allergic to penicillins and their
derivatives.
The 2007 AHA guideline describes in great detail specific situations that could require changes
to the application of the prophylactic regimens in clinical practice. For example, intramuscular
injections should be avoided in patients receiving anticoagulants. In patients attending the
dental clinic whilst on treatment with penicillins for other causes, it is preferable to delay dental
therapy for at least 10 days; it is accepted that viridans group streptococci in the oral cavity of
patients on long-term antibiotic therapy could be relatively resistant to penicillin or amoxicil-
lin, and the cessation of antibiotic therapy allows the usual oral flora to be re-established. When
the dental intervention cannot be postponed, the health professional should select a different
class of antibiotic rather than increase the dose of the current antibiotic; options include
clindamycin, azithromycin and clarithromycin, though only for patients with the highest-risk
cardiac conditions [11].
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Azithromycin and clarithromycin are macrolides with similar activity to erythromycin on the
oral streptococci, but they show better gastrointestinal tolerance and a more favourable
pharmacokinetic profile. Erythromycin is unstable under acidic gastric conditions, shows poor
absorption and has a limited spectrum of activity. Azithromycin, on the other hand, causes
fewer gastrointestinal side-effects, rapidly reaches high tissue concentrations and displays a
better antibacterial spectrum, making it a good candidate for IE prophylaxis [16].
The Australian guideline includes a parenteral regimen of lincomycin, vancomycin or
teicoplanin for patients with penicillin hypersensitivity and for those on long-term penicillin
therapy or who have taken penicillin or related β-lactam antibiotics more than once in the
previous month [12].
Finally, the ESC guideline is the most restrictive, recommending clindamycin as the only
alternative antibiotic. In contrast to the proposal of the Australian expert committee, the
European guideline states that the glycopeptides, such as vancomycin and teicoplanin, are not
recommended because their efficacy has not been fully demonstrated and there is a potential
for the induction of resistance [13].
4. At-risk patients
In its conclusions, the 2007 AHA guideline states that IE prophylaxis for dental procedures is
a reasonable practice only for patients with underlying heart conditions associated with the
highest risk of an adverse outcome [11]. New pathophysiological concepts and risk-benefit
analyses justify the current tendency of the scientific community towards more limited
indications for antibiotic prophylaxis in IE (Table 3).
1. Bacteraemia occurs repeatedly and frequently during routine daily activities such as toothbrushing, flossing or
chewing, and even more frequently in patients with poor dental health.
2. Most case-control studies did not report an association between invasive dental procedures and the occurrence of
infective endocarditis.
3. The estimated risk of infective endocarditis following dental procedures is very low.
4. Although antibiotic administration carries a small risk of anaphylaxis, it may become significant in the event of
widespread use.
5. Widespread use of antibiotics may result in the emergence of resistant microorganisms.
6. Although efficacy of antibiotic prophylaxis on bacteraemia and the occurrence of infective endocarditis has been
proven in animal models, the effect on bacteraemia in humans is controversial.
7. No prospective randomised controlled trial has investigated the efficacy of antibiotic prophylaxis on the occurrence
of infective endocarditis.
Table 3. Arguments for the restriction of the indication for prophylaxis against infective endocarditis [13].
Epidemiological evidence also supports this restrictive policy, as the incidence of IE and its
associated mortality have not varied in recent decades despite the use of antibiotic prophylaxis.
At the present time, we are seeing an increase in the number of cases of IE due to Staphylococcus
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aureus and of unknown aetiology and a fall in the incidence of cases of IE of streptococcal
aetiology [17]. This has occurred despite the evident, considerable increase in the number of
dental interventions and in the ratio of dentists to population in recent years.
In this context and awaiting relevant new data, NICE in the UK continues its recommendation
to universally cease antibiotic prophylaxis for medical interventions, although the majority of
cardiologists and cardiac surgeons consider antibiotic prophylaxis necessary for patients at
highest risk of adverse outcomes from endocarditis [9].
• Isolated secundum atrial septal defect.
• Surgical repair of atrial septal defect, ventricular septal defect, or patent ductus arteriosus (without residua beyond 6
months).
• Previous coronary artery bypass graft surgery.
• Mitral valve prolapse without valvar regurgitation.
• Physiologic, functional or innocent heart murmurs.
• Previous Kawasaki disease without valvar dysfunction.
• Previous rheumatic fever without valvar dysfunction.
• Cardiac pacemakers (intravascular and epicardial) and implanted defibrillators.
Table 4. Patients in whom prophylaxis against infective endocarditis is not recommended [18].
The 1997 AHA guideline was the first to stratify cardiac conditions into high, moderate and
low risk for IE [18]. AHA experts stated that the risk of suffering IE assumed by low-risk
patients undergoing dental treatment could be considered negligible, no higher than in the
general population, and, as a result, they recommended abolishing antibiotic prophylaxis for
routine dental treatment in these patients. This 1997 recommendation was particularly helpful
in clinical practice because heart murmurs, pacemakers and minor congenital defects were
frequently reported by dental patients in their medical records. The establishment of a
restrictive position on the part of the health authorities regarding antibiotic prophylaxis
created a framework of medico-legal protection in dental practice. The 1997 AHA guideline
thus provided dentists with a certain capacity to evaluate the prescription of prophylaxis in
patients with a history of cardiac disease and moderate their natural tendency to prescribe
universal antibiotic cover derived from a fear of missing one of the numerous indications
(Table 4). This conceptual change was further strengthened 10 years later when the 2007 AHA
committee eliminated antibiotic prophylaxis for patients considered to be in the moderate risk
category in the 1997 guideline (Table 5), on the basis that “previously published AHA guidelines
for the prevention of IE contained ambiguities and inconsistencies and were often based on minimal
published data or expert opinion, they were subject to conflicting interpretations among patients,
healthcare providers, and the legal system about patient eligibility for prophylaxis and whether there
was strict adherence by healthcare providers to AHA recommendations for prophylaxis” [11].
The current result of this policy limiting the indications for antibiotic prophylaxis to the highest
risk cardiac conditions is stated even more restrictively in the 2015 ESC guideline (Table 6). In
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their recommendation, the ESC excludes prophylaxis even in heart transplant recipients who
develop heart valve disease; this is considered a true high-risk condition in the AHA and
Australian guidelines. The Australian recommendations also include rheumatic heart disease
in indigenous Australians, a population in which unusually high prevalence and mortality
related to this disease have been detected [19].
• Congenital cardiac conditions
✓ Ductus arteriosus
✓ Ventricular septal defect
✓ Ostium primum atrial septal defect
✓ Coarctation of the aorta
✓ Bicuspid aortic valve
• Acquired valve dysfunction
✓ Rheumatic
✓ Collagen vascular disease
✓ Others
• Hypertrophic cardiomyopathy
• Mitral valve prolapse with valve regurgitation and/or thickened leaflets
Table 5. Cardiac conditions that carry a moderate risk of infective endocarditis [18].
Finally, dental surgeons show a degree of concern over the need for prophylaxis when per-
forming dental procedures on patients with implanted cardiac devices such as pacemakers,
stents and implantable defibrillators. In 2007, Lockhart et al. published an interesting litera-
ture review on this subject, revealing widely differing opinions, a situation that usually
leads dentists to contact physicians for advice on management. Interestingly, most physi-
cians, surgeons and medical specialists want their patients to receive antibiotic prophylaxis
for all invasive dental procedures to prevent distant site infection of organs, tissues or pros-
thetic materials, and a number of them do so for medico-legal rather than scientific reasons.
The majority of the literature sources agree that there is no indication for prophylaxis in
patients with cardiac devices. Bacterial seeding of a graft site via a haematogenous route is
an uncommon event and most of infections occurring in the first 2 months are due to Staph‐
ylococcus spp. and non-oral bacteria, probably as result of the manoeuvres of graft place-
ment [20].
Based on these premises, it could be stated that patients with implantable cardiac devices may
be cautiously covered with antibiotic prophylaxis exclusively during the early post-implan-
tation period, though this is mainly for medico-legal reasons. Considering the current IE
prophylaxis guidelines, there is no reason for antibiotic use during routine dental treatment
in patients with implantable cardiac devices, unless individual cases present concomitant
diseases that could justify such a decision.
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1. Patients with any prosthetic valve, including a transcatheter valve, or those in whom any prosthetic material was
used for cardiac valve repair.
2. Patients with a previous episode of infective endocarditis.
3. Patients with congenital heart disease (CHD):
a. Any type of cyanotic CHD.
b. Any type of CHD repaired with a prosthetic material, whether placed surgically or by percutaneous
techniques, up to 6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains.
Table 6. Cardiac conditions associated with the highest risk of adverse outcomes of endocarditis according to the
European Society of Cardiology guideline [13].
5. Risk-related dental procedures
In 1935, Okell and Elliott detected positive blood cultures in more than half of patients
undergoing dental manipulations, with a particularly high prevalence among those with
deficient oral health. Since that time, the relationship between bacteraemia of oral origin and
dental interventions constituted proof that endocardial infection could be precipitated by oral
streptococci mobilised during dental manipulation [21].
Transient bacteraemia has been widely documented as a common finding during dental
procedures, associated particularly with the manipulation of teeth and periodontal tissues.
Non-surgical tooth extraction is the dental procedure that most frequently provokes bacter-
aemia of oral origin, with a detection rate of positive blood cultures of 58–100% (Figure 1).
Figure 1. Prevalence of oral bacteraemia after dental procedures (inferred from [11]).
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From early studies, it was generally accepted that the incidence and magnitude of bacteraemia
of oral origin during dental procedures was directly proportional to the degree of inflammation
and infection in the mouth. However, more recent series have found no relationship between
the number of caries or the presence of periapical lesions and increased risk of post-interven-
tion bacteraemia. Similarly, it is also accepted that the grade of gingival and periodontal health
does not affect the presence or intensity of bacteraemia during interventions, and an increase
in the prevalence of bacteraemia has only been demonstrated after tooth extractions in the
setting of an acute infectious condition.
Studies that have investigated the bacteriological spectrum of bacteraemia of oral origin show
a wide variability in their results due to the different sampling and detection techniques
employed. However, Streptococcus spp.—the bacterial species most frequently implicated in IE
of oral origin—is detected in at least 30% of cases [22]. This inoculum of streptococci that
reaches the bloodstream has intrinsic pathogenic potential to colonise susceptible endocardial
tissue in highest-risk patients. Structurally, streptococci have surface proteins (adhesins) that
have been shown experimentally to have high affinity for the extracellular matrix, making the
microorganisms capable of easily colonising vegetations and medical devices that become
coated with matrix proteins after implantation. After colonisation, the bacterial biofilm acts as
a propitious environment to perpetuate infection. The resulting fibrin and platelet deposition
over the biofilm contributes to organise an actual bacteria-release clot which is able to create
the recurrent bacteraemias that characterise IE.
A number of experimental studies have been able to reproduce these pathological events in
animal models, but it remains to be seen whether oral bacteraemia secondary to dental
interventions could promote identical results in humans [23].
A prospective study recently performed on patients diagnosed with IE appears to indicate that
the mouth is a potential portal of entry (POE) for IE. A sample of 318 patients diagnosed with
IE was examined prospectively by different specialists selected according to the natural habitat
or site of colonisation of the causal diagnosed microorganism. A potential oral POE was
detected by a stomatologist in 68 cases (21%), of which only 12% were considered possibly
related to previous professional manipulation. Interestingly, the highest percentage of patients
(88%) with oral and dental POEs was therefore made up of patients with no history of dental
interventions. It was assumed that these patients presented a deficient state of oral health in
the form of dental, endodontal or periodontal infection (Table 7).
These results agree strongly with those of Lockhart et al. [11] who presented a comparative
study on the presence of bacteraemia in patients undergoing tooth extractions and tooth-
brushing. They found that the risk of oral bacteraemia was significantly associated with poor
oral hygiene during toothbrushing. However, they did not find any association in the extrac-
tion group, even when performed without antibiotic cover. This is consistent with statements
that patients at risk of IE have greater exposure to the action of oral bacteria during activities
of daily living, such as toothbrushing or chewing, particularly if the individual has poor oral
hygiene.
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N %
Related to dental procedures (previous 3 months) 8 12
Tooth extraction 4 6
Scaling 1 1.5
Endodontics 1 1.5
No details 2 3
Not related to dental procedures 60 88
Dental focus of infection (decay, fracture, trauma) 9 13.3
Dental focus of infection (no further details) 22 32.1
Periodontal disease 7 10.3
Endodontal and periodontal disease 12 17.5
Radiological dental infectious focus with no clinical lesion 9 13.3
Vigorous tooth brushing with frequent bleeding 1 1.5
Table 7. Infective endocarditis patients with identified oral and dental portals of entry (n = 68) [24].
These observations highlight the importance of maintaining oral hygiene in patients at highest
risk of IE, and provide an important argument that dental care could have greater repercus-
sions than antibiotic prophylaxis on the incidence of IE of oral origin.
6. Evidence of the efficacy of antibiotic prophylaxis
Since the 1955 AHA statement, Ref. [2] antibiotic prophylaxis has been continuously recom-
mended to clinicians for IE prevention among patients undergoing interventional medical
procedures. Since that early paper, antibiotic prophylaxis for IE has been considered “good
medical and dental practice” and it has been said that the “exact dosage and duration of
therapy are somewhat empirical”. Now, more than 50 years later, AHA experts continue to
consider that the basis for the recommendations for IE prophylaxis are still not well established
and that the quality of evidence is based on expert opinion, a few case-controlled studies,
clinical experience and descriptive studies [11]. All these circumstances lead antibiotic
prophylaxis against IE to be included in class C evidence (Table 8).
Level A Data derived from multiple randomised clinical trials or meta-analyses
Level B Data derived from a single randomised trial or non-randomised studies
Level C Only expert consensus, case studies or standard of care
Table 8. Classification of the levels of evidence.
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Despite this, intense research into this subject has been undertaken from three main perspec-
tives:
• The prevention of bacterial endocarditis in experimental animal models.
• The efficacy of antibiotics for the prevention of bacteraemia secondary to dental procedures.
• Epidemiological studies.
6.1. The prevention of bacterial endocarditis in experimental animal models
The induction of IE in experimental animals was first achieved in 1970. The technique consisted
of introducing a polyethylene catheter into the right side of the heart of the animal to induce
a nonbacterial thrombotic endocarditis. Bacteria were then injected via the catheter to induce
experimental bacterial endocarditis that served as a suitable model for the study of bacterio-
logical, pathological and immunological aspects of IE [25].
Although experimental studies make it possible to investigate the efficacy of prophylactic
antibiotic regimens against IE, there are difficulties associated with animal models both in their
methodology and in the extrapolation of results. The plastic catheter acts as a foreign body
delaying the successful treatment of established infection in animals, and the pharmacokinetics
of antimicrobials in animals differ considerably from those in man [26].
The percentage of positive post-extraction blood cultures in experimental animals receiving
antibiotic prophylaxis fell slightly with respect to the controls. However, it was observed that
the administration of amoxicillin effectively prevented the onset of IE, allowing the researchers
to suggest that the antibiotics had some protective mechanism over and above their bactericidal
activity.
Animal research continues to be very useful for the preliminary evaluation of the efficacy and
safety of drugs, and studies are being performed on the usefulness of other, alternative drugs
to antibiotics for the prevention of IE in at-risk patients [27].
6.2. Efficacy of antibiotics in the prevention of bacteraemia secondary to dental procedures
The majority of studies show that amoxicillin is effective in the control of bacteraemia of oral
origin, reducing the rate of positive blood cultures after dental interventions in a range that
varies between 70 and 100%. There are a number of reports on the efficacy of alternative
antibiotics to amoxicillin for the prevention of bacteraemia of oral origin. Results are hetero-
geneous as they are conditioned by numerous factors such as geographical situation, previous
patient oral health status, blood culture sampling technique, microbiological analysis,
resistance maps, etc.; however, in general, alternative antibiotics show a lower efficacy in the
control of bacteraemia.
Interestingly, clindamycin constitutes the alternative antibiotic of choice to amoxicillin in the
three main guidelines (AHA, ESC and AIEPEG). Although some studies have concluded that
clindamycin was useful to reduce oral bacteraemia, more recently published studies have
found that clindamycin prophylaxis does not produce a significant reduction in the incidence
Antibiotic Prophylactic Regimens for Infective Endocarditis in Patients Undergoing Dental Procedures
http://dx.doi.org/10.5772/65255
27
of oral bacteraemia during dental procedures [15, 28, 29]. Some authors have proposed
moxifloxacin as an alternative to amoxicillin, given its efficacy in experimental endocarditis
[30] and in the prevention of bacteraemia following dental procedures in humans [15].
However, endocarditis expert committees appear to be ignoring this antibiotic at the present
time.
S. aureus is now the most common pathogen in IE. This circumstance could justify the use of
amoxicillin in association with a β-lactamase inhibitor, such as clavulanate, to broaden the
bactericidal spectrum of antibiotic prophylaxis against IE. A recent study suggests that
intravenous amoxicillin/clavulanate could be effective in the prevention of oral bacteraemia,
virtually eliminating post-procedure inocula [29]. This observation opens the door to further
research into the efficacy of oral amoxicillin/clavulanate in the prevention of bacteraemia. In
any case, given its unusual demonstrated effectiveness in the elimination of oral bacteraemia,
the intravenous prophylactic regimen of amoxicillin/clavulanate could be a high-efficacy
alternative for patients with cardiac risk factors and severe systemic alterations, such as
immune compromise, who require curative interventional dental treatment.
6.3. Epidemiological studies
Up to 2008, epidemiological studies did not support the hypothesis for the use of prophylactic
antibiotics for medical procedures as a preventive method against IE. Case-control studies
indicated that most IE events occurred independently of medical interventions and of the
administration of antibiotic prophylaxis. A further argument was that despite the universal
application of antibiotic prophylaxis, the incidence of IE and its associated mortality had not
varied over decades [5].
In 2008, cessation of the NICE recommendation for antibiotic prophylaxis introduced a new
epidemiological context into the study of IE, and analysis will serve to establish reliable
conclusions in its area of influence. Implementation of the NICE guideline in England provides
an opportunity for retrospective studies to investigate the comparative effect of antibiotic
prophylaxis versus no prophylaxis on the incidence of IE.
Initially, the data suggest a significant increase in the incidence of IE after implantation of the
NICE guideline, rising above the projected historical trend. This observation could lead to the
hypothesis that the increased incidence of IE could be related to medical procedures in
susceptible individuals performed without appropriate antibiotic cover. With regard to the
dental procedures, we should observe an increase in the incidence of IE caused by oral viridans
group streptococci but, at the present time, no data are available on pathogen-specific causal
microorganisms [30].
7. Detractors of antibiotic prophylaxis
In view of the lack of scientific evidence on the prophylactic efficacy of the antibiotics for the
prevention of IE, the British health authorities have focused their attention on the principle
problems of the indiscriminate administration of antibiotics [6]:
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• Quantifiable risk to the individual patient.
• Creation of unnecessary antimicrobial resistance.
• Economic burden.
However, a recent study on the incidence and nature of adverse reactions to antibiotics
prescribed for endocarditis prophylaxis in England from 2004 estimates that reported adverse
drug reaction rates from amoxicillin prescribed as antibiotic prophylaxis are low, without a
single fatal reaction for nearly 3 million prescriptions [31].
The emergence of antibiotic resistance is a serious public health problem, but prophylactic
antibiotic regimens for IE would only have a very limited effect as evidence shows that bacteria
acquire resistance to antibiotics only after the administration of several consecutive doses.
With regard to the cost to the national health systems of the systematic administration of
prophylaxis, cost-efficacy analyses of antibiotic prophylaxis for at-risk patients undergoing
dental treatment provided contradictory results. In some countries, such as the USA, it has
been estimated that prophylaxis constitutes a considerable expense, [32] but their results
cannot be extrapolated to other countries in which the administration of prophylactic antibi-
otics to high-risk patients only represents a very small percentage of all the antibiotics that
dentists prescribe.
Research into the control of bacteraemia shows that the administration of amoxicillin signifi-
cantly reduces bacteraemia of oral origin, though it does not completely eliminate the possi-
bility that this could occur. Alternative antibiotics such as clindamycin have shown poor results
in the reduction of bacteraemia after dental interventions, leading us to deduce that the efficacy
of prophylactic antibiotics in the prevention of IE in high-risk patients undergoing dental
manipulations is limited.
8. Future research
Studies published to date on antibiotic prophylaxis against IE have a series of limitations that
hinder their extrapolation, and attention must be focused on this aspect in future research:
• Regarding participants, it has been suggested that the prevalence of post-extraction
bacteraemia may be related to age [33]. Age is also a determining factor in the pharmaco-
kinetics of the antibiotic, and the efficacy of specific prophylaxis regimens may differ
between children and adults. The oral health status may also influence the prevalence of
post-dental manipulation bacteraemia, although this is still a controversial issue [34].
• The mode of anaesthesia, particularly general anaesthesia, can determine the appearance of
post-extraction bacteraemia and prolong its duration. Comparative studies should therefore
be performed using local and general anaesthesia [35].
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• The prevalence of bacteraemia secondary to dental treatment and probably the predominant
bacterial species are determined by the nature of the procedure. We therefore do not know
whether antibiotic prophylaxis will be equally effective for different dental procedures [22].
• It is not known whether the dose and route of administration for the majority of current
antibiotic prophylaxis regimens has a bearing on antibacterial activity.
• The fact that positive post-dental-manipulation blood cultures are not detected after the
administration of antibiotic prophylaxis does not guarantee that bacteraemia does not occur
due to bacteria that cannot be cultured in the usual culture media and/or whose inoculum
is below the threshold of the method of detection employed.
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